UpToDate Contents

全文を閲覧するには購読必要です。 To read the full text you will need to subscribe.

1. 持続的腹膜透析における溶質クリアランスの測定：Kt/Vとクレアチニンクリアランスmeasurement of solute clearance in continuous peritoneal dialysis kt v and creatinine clearance [show details]
… area (BSA). Both Kt/V and CCr utilize clearance of a surrogate solute (ie, urea or creatinine, respectively) to estimate overall small solute clearance. The weekly Kt/Vurea is now the preferred method for …
2. 腹膜透析での溶質除去不足inadequate solute clearance in peritoneal dialysis [show details]
… BUN. Two metrics are commonly used to measure solute clearance by peritoneal dialysis. These include the weekly Kt/Vurea and the creatinine clearance normalized to body surface area . We use the Kt/Vurea …
3. 腎不全における炎症inflammation in renal insufficiency [show details]
…route of elimination for anakinra is renal clearance and that hemodialysis has a very small effect on clearance . The results of this study indicate that thrice-weekly dosing of anakinra may be possible. The …
4. 腹膜透析の処方prescribing peritoneal dialysis [show details]
…dialysis for the total achieved weekly Kt/Vurea: In this example, the patient residual kidney function provides a substantial contribution to the total weekly clearance. If this patient loses residual …
5. 慢性腹膜透析を導入する患者の評価と透析の種類の選択evaluating patients for chronic peritoneal dialysis and selection of modality [show details]
…patients must also do a midday exchange (ie, two daytime dwells) to achieve adequate solute clearance . Weekly clearances are similar to those obtained with CAPD, but some evidence suggests that ultrafiltration …

English Journal

Single dose oral ranolazine pharmacokinetics in patients receiving maintenance hemodialysis.

Scoville BA, Segal JH, Salama NN, Heung M, Bleske BE, Eyler RF, Mueller BA.
Renal failure. 2019 Nov;41(1)118-125.
Ranolazine is a novel anti-angina treatment approved in the United States for chronic stable angina. Ranolazine pharmacokinetics have not been studied previously in patients who receive maintenance hemodialysis. This study describes the pharmacokinetics of ranolazine and three major metabolites (CVT
PMID 30909832

First-in-human phase I study of infusional and bolus schedules of Deflexifol, a novel 5-fluorouracil and leucovorin formulation, after failure of standard treatment.

Clingan PR, Ackland SP, Brungs D, de Souza P, Aghmesheh M, Garg MB, Ranson RD, Parker S, Jokela R, Ranson M.
Asia-Pacific journal of clinical oncology. 2019 Jun;15(3)151-157.
5-Fluorouracil (5-FU) is administered with leucovorin (LV) to enhance clinical activity. However, simultaneous administration is not feasible due to their chemical incompatibility, so conditions for the maximum possible beneficial interaction cannot be met. To overcome this, we developed a novel all
PMID 30843362

Clinical and translational pharmacology of the cathepsin K inhibitor odanacatib studied for osteoporosis.

Stone JA, McCrea JB, Witter R, Zajic S, Stoch SA.
British journal of clinical pharmacology. 2019 Jun;85(6)1072-1083.
Cathepsin K (CatK) is a cysteine protease abundantly expressed by osteoclasts and localized in the lysosomes and resorption lacunae of these cells. CatK is the principal enzyme responsible for the degradation of bone collagen. Odanacatib is a selective, reversible inhibitor of CatK at subnanomolar p
PMID 30663085

Japanese Journal

Tissue distribution of indium after repeated intratracheal instillations of indium-tin oxide into the lungs of hamsters

TANAKA Akiyo,HIRATA Miyuki,MATSUMURA Nagisa [他],Kiyohara Yutaka
ｊｏｕｒｎａｌ　ｏｆ　Ｏｃｃｕｐａｔｉｏｎａｌ　Ｈｅａｌｔｈ 57(2), 189-192, 2015
… Male Syrian hamsters received an intratracheal dose of 3 mg/kg or 6 mg/kg of ITO particles containing 2.2 mg/kg or 4.5 mg/kg of indium, twice weekly for 8 weeks. … The results clearly demonstrate that the clearance of indium from the body is extremely slow after intratracheal instillation in hamsters.(J Occup Health 2015; …
NAID 130005066083

Clinical Pharmacokinetics and Effects of Vincristine Sulfate in Dogs with Transmissible Venereal Tumor (TVT)

HANTRAKUL Supannika,KLANGKAEW Narumol,KUNAKORNSAWAT Sunee,TANSATIT Tawewan,POAPOLATHEP Ammart,KUMAGAI Susumu,POAPOLATHEP Saranya
Ｔｈｅ　Ｊｏｕｒｎａｌ　ｏｆ　Ｖｅｔｅｒｉｎａｒｙ　Ｍｅｄｉｃａｌ　Ｓｃｉｅｎｃｅ 76(12), 1549-1553, 2014
… The volume of distribution, distribution half-life, elimination half-life and plasma clearance were 0.660 ± 0.210 l/kg, 21.5 ± 6.90 min, 47.6 ± 14.2 min and 0.010 ± 0.001 l/min/kg, respectively. … Tumor regression was determined at weekly interval by a physical examination and histopathological analysis. …
NAID 130004677731

腹膜透析患者の残腎機能におけるシスタチンCの検討

齋藤篤史,田畑勉,辻本吉広 [他],藤原木綿子,細見由佳,上田恵利子,伊藤淑子,安田雅子,山内裕二
日本透析医学会雑誌 = Journal of Japanese Society for Dialysis Therapy 44(9), 939-944, 2011-09-28
… microglobulin，以下β2MG）と比較検討した．血清CysC値と週当たりの腎Kt/Vurea（r＝－0.39，p＜0.0001），週当たりの腎クレアチニンクリアランス（creatinine clearance，以下CCr）（r＝－0.38，p＜0.0001），GFR（r＝－0.38，p＜0.0001），24時間尿量（r＝－0.19，p＝0.024）と，ともに有意な負の相関関係を認めた．血清β2MG値も週当たりの腎Kt/Vurea（r＝－0.69，p＜0.0001），週当 …
NAID 10029747367